How to Read FDA and State Board Sources for Peptide Programs

Federal permission language never replaces a state board that refuses the shipment.

Step 5: Medical board / supervision (15 minutes)

Pharmacy boards do not answer medical director questions. For med spas and collaborative practice, start with your state medical board and FSMB reference material at fsmb.org. The med spa launch guide covers why the prescriber has to own the program before marketing does.

Step 6: Turn reading into artifacts

After the reading block, you should have three files (even if they are short):

• Status sheet — one sentence per compound, band labeled allowed / grey / not allowed.
• Source appendix — URLs with access dates.
• Pharmacy ask list — the exact compounds you need written authority for.

Counsel works faster when you bring those three instead of a folder of screenshots. Signed-in PeptIQ clinics can keep related matrix rows in Education → Legal Reference; the public hub is for the pre-login conversation.

Reading mistakes that create false confidence

• Treating a PCAC vote as a final FDA rule. It is not. See Category 1 interim access.
• Treating an approved-drug shortage memo as forever.
• Treating another state's pharmacy letter as authority in your state.
• Treating PeptIQ Education content as clearance. Software tracks and teaches. It does not prescribe or legalize a vial.

See the provider console

PeptIQ.io for providers is a provider console plus the PeptIQ patient app: protocol templates with phases, patient dose and vial logging, an adherence roster with nudges, staff roles across locations, vial flags, Provider AI, and a revenue forecast from active protocols. It is not an EHR and it does not sell peptides.

• Book a 30-minute demo using your locations and use case.
• Read the provider overview or start self-serve at provider.peptiq.io/get-started (20-seat minimum, prepaid 3, 6 or 12 month terms; full table on /providers/pricing).

Frequently Asked Questions

Q: How often should we re-check FDA pages?

A: Before any menu expansion, and at least when shortage status or PCAC/FDA compounding pages change. Put an owner on the status sheet.

Q: Are secondary explainers useless?

A: No. Use them after the primary page, as a map. Our Provider Resources hub is built that way on purpose.

Q: What if the pharmacy will not put authority in writing?

A: Treat the compound as not ready. Verbal comfort is not a status sheet.

Q: Where do sales teams send prospects who want "the docs"?

A: /providers/resources/sources plus the status bands tool, then book a demo only if they want the console workflow.

Sources

• FDA compounding overview
• FDA 503A bulk substances
• FDA safety-risk bulks
• FDA unapproved GLP-1 concerns
• FDA drug shortages
• NABP boards of pharmacy
• PeptIQ source library

This article is educational content from PeptIQ for clinic operators. It is not medical, legal, or regulatory advice. Prescribing, compounding, and consent decisions belong with licensed clinicians, pharmacists, and your counsel. PeptIQ does not sell, source, or dispense peptides.